# Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections

> **NCT00057369** · PHASE2 · UNKNOWN · sponsor: **Vicuron Pharmaceuticals** · enrollment: 88 (—)

## Conditions studied

- Bacteremia

## Interventions

- **DRUG:** dalbavancin

## Key facts

- **NCT ID:** NCT00057369
- **Lead sponsor:** Vicuron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2001-02
- **Primary completion:** —
- **Final completion:** 2003-06
- **Target enrollment:** 88 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00057369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00057369, "Safety and Efficacy of Dalbavancin Versus Vancomycin in the Treatment of Catheter-Related Bloodstream Infections". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00057369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*